Journals / Journal of Neurological Sciences (Turkish) / 2012 / Cilt: 29 - Sayı: 3

Fotemustin ve Genisteinin Glioblastom Multiforme Hücre Hattında p53, EGFR ve COX-2 Genlerinin Ekspresyonları Üzerine Sinerjistik Etkisi

The Synergistic Effect of Fotemustine and Genistein on Expressions of p53, EGFR and COX-2 Genes in Human Glioblastoma Multiforme Cell Line

Pages
510–517
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This study wasalso designed to answer the following question: Do the p53, EGFR, COX-2 genes' expressionpatterns differ in treatment of these both drugs alone and in combination?

📌 3 Key Takeaways

🎯
Objective & Hypothesis:GBM is the most common primary malignant neoplasm of the central nervous system inadults.
📊
Key Findings & Data:We aimed to investigate the anti-proliferative synergistic effect ofgenistein with fotemustine on human glioblastoma multiforme U87-MG cells.
💡
Conclusion & Impact:This study wasalso designed to answer the following question: Do the p53, EGFR, COX-2 genes' expressionpatterns differ in treatment of these both drugs alone and in combination?
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

GBM is the most common primary malignant neoplasm of the central nervous system inadults. Fotemustine (FTM) is a cytotoxic alkylating agent and a lipophilicchloroethylnitrosourea derivative. Its mechanism of action consists mainly in inducing DNAstrand breaks and cross-linking. Genistein, one of the soy-derived isoflavones, exerts itsanticancer properties via several mechanisms, including inhibition of tyrosinephosphorylation, weak estrogenic and anti-estrogenic properties, as an antioxidant, inhibitionof topoisomerase II, inhibition of angiogenesis, and induction of cell differentiation in anumber of human tumors. We aimed to investigate the anti-proliferative synergistic effect ofgenistein with fotemustine on human glioblastoma multiforme U87-MG cells. This study wasalso designed to answer the following question: Do the p53, EGFR, COX-2 genes' expressionpatterns differ in treatment of these both drugs alone and in combination?

Özet

GBM yetişkinlerde merkezi sinir sisteminin en yaygın primer malin neoplazmıdır. Fotemustin(FTM) sitotoksik bir ajan ve lifofilik kloroetilnitrozüri türevidir. DNA zincir kırıklarını veçapraz bağlanmayı indüklemek ana mekanizmasını oluşturmaktadır. Soyadan elde edilen birisoflavon olan Genistein, antikanser özelliğini tirozin fosforilasyonunun inhibisyonu, zayıföstrojenik ve anti-östrojenik özellikleri, antioksidan olarak, topoizomeraz II' nin inhibisyonu,anjiyogenezin inhibisyonu ve hücre faklılaşmasının başlaması gibi çeşitli mekanizmalar ilegöstermektedir. Genisteinin fotemustin ile anti-proliferatif sinerjistik etkisinin insanglioblastoma multiforme U87-MG hücrelerinde incelenmesi amaçlanmıştır. Bu çalışma ayrıcap53, EGFR, COX-2 gen ekspresyon paternlerinin bu ilaçların ayrı ayrı veya kombinekullanılmasının ardından faklılık gösterip göstermediğine cevap verebilmek içintasarlanmıştır.

🔖

Cite This Article

GÜNDÜZ, C., YILMAZ, S. S., AVCI, Ç. B., OKTAR, N., DOĞAN, Z. Ö. Ş., DODURGA, Y. (2022). Fotemustin ve Genisteinin Glioblastom Multiforme Hücre Hattında p53, EGFR ve COX-2 Genlerinin Ekspresyonları Üzerine Sinerjistik Etkisi. Journal of Neurological Sciences (Turkish), Cilt: 29 - Sayı: 3, 510–517. https://ajindex.com/articles/565223

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Badie B, Schartner JM, Hagar AR, Prabakaran S, Peebles TR, Bartley B, Lapsiwala S, Resnick DK, Vorpahl J (2003) Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema f ormation. Clin Cancer Res 9:872– 877 2. Buccoliero AM, Caldarella A, Arganini L, Mennonna P, Gallina P, Taddei A, Taddei GL (2004) Cyclooxygenase-2 in oligodendroglioma: possible prognostic signif icance. Neuropathology 24:201–207 3. Chakravarti A, Seif erheld W, Tu X, Wang H, Zhang HZ, Ang KK, Hammond E, Curran W Jr, Mehta M (2005) Immunohistochemically determined total epidermal growth f actor receptor levels not of prognostic value in newly diagnosed glioblastoma multif orme: report f rom the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 62:318–327 4. Colgan SP, Taylor CT, Narravula S, Synnestvedt K, Blume ED (2002) Endothelial COX-2 induction by hypoxia liberates 6-keto-PGF1 alpha, a potent epithelial secretagogue. Adv Exp Med Biol 507:107–112
  2. Davis TW, O'Neal JM, Pagel MD, Zweif el BS, Mehta PP, Heuvelman DM, Masf errer JL (2004). Synergy between celecoxib and radiotherapy results f rom inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival f actor f or tumor and associated vasculature. Cancer Res 64:279–285 6. Dong L, Pu PY, Wang H, Wang GX, Kang CS, Jiao DR. Study on the expression of epidermal growth f actor receptor and p53 in astrocytic gliomas: evidence f or a distinct genetic pathway Zhonghua Bing Li Xue Za Zhi. 2006 Apr
  3. 35(4):232-6 7. Fabrini MG, Silvano G, Lolli I, Perrone F, Marsella A, Scotti V, Cionini L. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol. 2009 Mar
  4. 92(1):79-86 8. Halatsch ME, Schmidt U, Unterberg A, Vougioukas VI. Unif orm MDM2 overexpression in a panel of glioblastoma multif orme cell lines with divergent EGFR and p53 expression status. Anticancer Res. 2006 Nov-Dec
  5. 26(6B):4191-4 9. Hara A, Okayasu I (2004) Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic signif icance. Acta Neuropathol (Berl) 108:43–48), 10. Hoozemans J, Veerhuis R, Janssen I, Van Elk EJ, Rozemuller AJ, Eikelenboom P (2002) The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E(2) secretion by cultured human adult microglia: implications f or Alzheimer's disease. Brain Res 951:218–226 11. Hulsebos TJ, Troost D, Leenstra S (2004) Molecular-genetic characte